These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2322593)

  • 1. Biotransformation of mafosfamide in P388 mice leukemia cells: intracellular 31P-NMR studies.
    Sonawat HM; Leibfritz D; Engel J; Hilgard P
    Biochim Biophys Acta; 1990 Apr; 1052(1):36-41. PubMed ID: 2322593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 31P nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites.
    Boyd VL; Robbins JD; Egan W; Ludeman SM
    J Med Chem; 1986 Jul; 29(7):1206-10. PubMed ID: 3543359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
    Low JE; Borch RF; Sladek NE
    Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and the concomitant partitioning of aldophosphamide between irreversible fragmentation and reversible conjugation pathways.
    Zon G; Ludeman SM; Brandt JA; Boyd VL; Ozkan G; Egan W; Shao KL
    J Med Chem; 1984 Apr; 27(4):466-85. PubMed ID: 6708049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Phosphorus-containing metabolites in the cells of anthracycline-resistant strains of leukemia P388].
    Shiriaeva OA; Semenova NA; Sibel'dina LA; Goncharova SA; Konovalova NP
    Eksp Onkol; 1989; 11(4):70-3. PubMed ID: 2759015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antitumor properties of activated cyclophosphamide analogues.
    Borch RF; Canute GW
    J Med Chem; 1991 Oct; 34(10):3044-52. PubMed ID: 1920355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.
    Friedman OM; Wodinsky I; Myles A
    Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Higashigawa M; Hori H; Ochiai H; Ohkubo T; Kawasaki H; Nobori T; Kamiya H; Sakurai M
    Adv Exp Med Biol; 1989; 253B():341-8. PubMed ID: 2610121
    [No Abstract]   [Full Text] [Related]  

  • 9. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines.
    Sladek NE; Landkamer GJ
    Cancer Res; 1985 Apr; 45(4):1549-55. PubMed ID: 3978623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine.
    Maki PA; Sladek NE
    Cancer Res; 1991 Aug; 51(16):4170-5. PubMed ID: 1868438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation mechanisms of mafosfamide and the role of thiols in cyclophosphamide metabolism.
    Kwon CH; Borch RF; Engel J; Niemeyer U
    J Med Chem; 1987 Feb; 30(2):395-9. PubMed ID: 3806619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Half-life of oxazaphosphorines in biological fluids.
    Sladek NE; Powers JF; Grage GM
    Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mechanism of activation of 4-hydroxycyclophosphamide.
    Borch RF; Millard JA
    J Med Chem; 1987 Feb; 30(2):427-31. PubMed ID: 3806624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor pharmacokinetics of hexamethylmelamine in CDF1 mice bearing P388 leukemia.
    Dubois J; Atassi G; Hanocq M; Abikhalil F
    Anticancer Res; 1989; 9(1):255-9. PubMed ID: 2495757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical characteristics of a 5-fluorouracil-resistant subline of P388 leukemia.
    Tezuka M; Sugiyama H; Tamemasa O; Inaba M
    Gan; 1982 Feb; 73(1):70-6. PubMed ID: 7117749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct detection of the intracellular formation of carboxyphosphamides using nuclear magnetic resonance spectroscopy.
    Boal JH; Ludeman SM; Ho CK; Engel J; Niemeyer U
    Arzneimittelforschung; 1994 Jan; 44(1):84-93. PubMed ID: 8135883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. General features of systemic effects of murine leukemias on phosphate metabolism in liver studied by 31P NMR.
    Yushmanov VE; Khristianovich DS; Rozantseva TV; Sibeldina LA
    NMR Biomed; 1992; 5(3):107-13. PubMed ID: 1642967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. O-Methylhydroxylamine as a new trapping reagent for quantitative studies of 4-hydroxycyclophosphamide and aldophosphamide.
    Zon G; Ludeman SM; Sweet EM; Egan W; Phillips LR
    J Pharm Sci; 1982 Apr; 71(4):443-6. PubMed ID: 7086655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple fluorometric method to discriminate adriamycin-resistant subline from adriamycin-sensitive parental P388 murine leukemia cell line.
    Dekker K; Kojima N; Yamamoto S; Tatsumi K; Mino M; Yagi K
    Biochem Int; 1987 Jun; 14(6):997-1001. PubMed ID: 3453100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gamma interferon administration differently affects sensitive or doxorubicin resistant P388 leukemia cells; a relationship with antioxidant defenses?
    Armata MG; Crescimanno M; Tapiero H; Rausa L; D'Alessandro N
    Pharmacol Res; 1989; 21 Suppl 1():21-2. PubMed ID: 2517339
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.